Product image of Levosimendan Bioglan (Levosimendan) supplied by GNH India

Levosimendan Bioglan

Active Ingredient:
Levosimendan
Origin:
EU

Levosimendan Bioglan (Levosimendan)

Levosimendan, the active ingredient in Levosimendan Bioglan, is a calcium sensitizer presented as an injection for intravenous use. It is employed in the management of acute decompensated heart failure to improve cardiac contractility and reduce symptoms in hospitalized patients.

GNH India supplies Levosimendan Bioglan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The product conforms to EU market standards and is manufactured under GMP conditions.

Manufacturer / TM Owner

Bioglan Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Levosimendan is indicated for conditions affecting cardiac contractility and systemic circulation.

  • Acute decompensated heart failure: improves cardiac output and alleviates symptoms in patients with sudden worsening of heart failure.
  • Cardiogenic shock: provides inotropic support to stabilize hemodynamics when conventional therapies are insufficient.
  • Post‑cardiac surgery low cardiac output syndrome: enhances myocardial performance to facilitate recovery after cardiac operations.

How It Works

  • Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting myocardial contractility without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous vasodilation. The combined inotropic and vasodilatory actions reduce preload and afterload, supporting cardiac output in heart‑failure states.

Side Effects

Levosimendan may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Hypotension: transient drop in blood pressure.
  • Tachycardia: increased heart rate.
  • Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

  • Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
  • Severe hypotension: marked blood pressure decline requiring intervention.
  • Myocardial ischemia: reduced blood flow to heart muscle.
  • Pulmonary edema: fluid accumulation in lungs.
  • Anaphylactic reaction: rare hypersensitivity requiring emergency care.

Precautions & Warnings

When using Levosimendan, clinicians should observe specific precautions to minimize risk.

  • Cardiac monitoring: continuous ECG and hemodynamic assessment during infusion.
  • Blood pressure: monitor for hypotension, especially in patients on vasodilators.
  • Electrolytes: correct potassium and magnesium abnormalities before administration.
  • Renal impairment: adjust use in severe renal dysfunction due to altered drug clearance.
  • Hepatic dysfunction: use cautiously in patients with significant liver disease.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations.
  • Nitrates: additive vasodilatory effect can cause severe hypotension.
  • Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely)

  • Diuretics: may potentiate hypotensive response.
  • Beta‑blockers: may blunt desired inotropic effect.
  • Calcium channel blockers: possible additive cardiovascular effects.

Frequently Asked Questions

Levosimendan Bioglan is used in the hospital setting to treat acute decompensated heart failure, cardiogenic shock, and low‑output states after cardiac surgery. By improving myocardial contractility and reducing vascular resistance, it helps stabilize patients whose heart function has suddenly deteriorated.

Levosimendan enhances the heart’s contractile force by binding to troponin C, making the contractile proteins more responsive to calcium. At the same time it opens ATP‑sensitive potassium channels in blood‑vessel walls, producing arterial and venous dilation, which together lower cardiac workload and improve output.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and renal function. Typically the drug is administered as an intravenous infusion, but exact rate, loading dose, and duration are individualized and should follow local protocols.

Safety data for levosimendan during pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

To place an order, submit an enquiry on the Levosimendan Bioglan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Unlike traditional catecholamine inotropes such as dobutamine, levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. It also adds vasodilatory effects, lowering afterload, whereas many other inotropes primarily act on heart muscle alone.

Levosimendan Bioglan must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The vial should remain in its original packaging until use to maintain stability and potency.

Levosimendan is given as an intravenous infusion, usually through a dedicated line. The infusion may start with a loading dose followed by a continuous maintenance infusion, all performed under continuous cardiac and hemodynamic monitoring in a controlled clinical environment.

The most critical safety concerns include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare anaphylactic reactions. Patients should be closely monitored for blood pressure changes, rhythm disturbances, and signs of inadequate coronary perfusion throughout the infusion.

Levosimendan is contraindicated in patients with severe hypotension, obstructive cardiac lesions (e.g., severe aortic stenosis), uncontrolled ventricular arrhythmias, or known hypersensitivity to the drug or its excipients. Caution is also advised in severe renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levosimendan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT